Company

ImmunoGen, Inc.

Headquarters: Waltham, MA, United States

Founded: 1981

Employees: 106

CEO: Mr. Mark Joseph Enyedy

NASDAQ: IMGN

Market Cap

$8.25 Billion

USD as of Jan. 1, 2024

Market Cap History

ImmunoGen, Inc. market capitalization over time

Evolution of ImmunoGen, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of ImmunoGen, Inc.

Detailed Description

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

ImmunoGen, Inc. has the following listings and related stock indices.


Stock: NASDAQ: IMGN wb_incandescent

Stock: FSX: IMU wb_incandescent

Financials

Revenue: $65.2 million (2019)

Details

Headquarters:

830 Winter Street

Waltham, MA 02451-1477

United States

Phone: 781 895 0600